DWP DT-2401

DWP DT-2401 is an investigational pharmaceutical candidate developed by Daewoo Pharma for the treatment of xerostomia, commonly known as dry mouth. As of 2024, the drug is in Phase 3 clinical development. Xerostomia is a condition characterized by reduced salivary flow, often occurring as a complication of Sjogren's syndrome or as a side effect of radiotherapy for head and neck cancers. While the specific active ingredient is not explicitly named in the company's high-level pipeline, drugs in this therapeutic category typically function as muscarinic acetylcholine receptor agonists (such as pilocarpine) to stimulate the secretion of salivary glands and alleviate oral dryness.

Other names

DT-2401-Daewoo-XerostomiaDT2401-Daewoo-XerostomiaDT 2401-Daewoo-Xerostomia